<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="7cde57a7-eded-4c22-b1c7-98afc5546997"><labelDrug name="Teveten"><Normalization><mmtx cui="C0876891" preferredWord="Teveten" semType="phsu, orch"/></Normalization></labelDrug><generic name="Eprosartan Mesylate"/><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.1" text="TEVETEN (eprosartan mesylate) tablet" type="negative"><entity charOffset="0:7" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.1.e.0" text="teveten" type="Biomedical_Entity"><Normalization><mmtx cui="C0876891" phraseText="TEVETEN" preferredWord="Teveten" semType="phsu, orch"/><RxNorm RxCui="262242"/></Normalization></entity><entity charOffset="9:28" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.1.e.1" text="eprosartan mesylate" type="Biomedical_Entity"><Normalization><mmtx cui="C0772203" phraseText="(eprosartan mesylate" preferredWord="Eprosartan mesylate" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.1.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.1.e.1"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.2" text="TEVETEN (eprosartan mesylate) is a non-biphenyl non-tetrazole angiotensin II receptor (AT1) antagonist." type="negative"><entity charOffset="62:76" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.2.e.0" text="angiotensin ii" type="Biomedical_Entity"><Normalization><mmtx cui="C0003009" phraseText="a non-biphenyl non-tetrazole angiotensin II receptor" preferredWord="Angiotensin II" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="9:28" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.2.e.1" text="eprosartan mesylate" type="Biomedical_Entity"><Normalization><mmtx cui="C0772203" phraseText="(eprosartan mesylate" preferredWord="Eprosartan mesylate" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="0:7" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.2.e.2" text="teveten" type="Biomedical_Entity"><Normalization><mmtx cui="C0876891" phraseText="TEVETEN" preferredWord="Teveten" semType="phsu, orch"/><RxNorm RxCui="262242"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.2.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.2.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.2.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.2.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.2.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.2.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5" lineNumber="9" text="Do not co-administer aliskiren with TEVETEN in patients with diabetes (see PRECAUTIONS, Drug Interactions)." type="regular"><entity charOffset="21:30" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.0" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren with TEVETEN" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="36:43" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.1" text="TEVETEN" type="Drug"><Normalization><mmtx cui="C0876891" phraseText="aliskiren with TEVETEN" preferredWord="Teveten" semType="phsu, orch"/><RxNorm RxCui="262242"/></Normalization></entity><entity charOffset="61:69" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.2" text="diabetes" type="SPAN"><Normalization><mmtx cui="C0011847" phraseText="with diabetes" preferredWord="Diabetes" semType="dsyn"/><mmtx cui="C0011849" phraseText="with diabetes" preferredWord="Diabetes Mellitus" semType="dsyn"/></Normalization></entity><entity charOffset="0:20" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.3" text="Do not co-administer" type="Caution_Interaction"/><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.ddi.1"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.3"><relations><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.0"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.2" ddi="true" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.1" trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.5.e.3" type="Caution_Interaction"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.14" text="Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. " type="negative"><entity charOffset="168:179" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.14.e.0" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="the renin-angiotensin system from other antihypertensive agents." preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="198:221" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.14.e.1" text="antihypertensive agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="the renin-angiotensin system from other antihypertensive agents." preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><entity charOffset="75:91" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.14.e.2" text="antihypertensive" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="to antihypertensive use" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.14.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.14.e.1"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.14.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.14.e.0"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.22" text="Eprosartan mesylate has been shown to produce maternal and fetal toxicities (maternal and fetal mortality, low maternal body weight and food consumption, resorptions, abortions and litter loss) in pregnant rabbits given oral doses as low as 10 mg eprosartan/kg/day. " type="negative"><entity charOffset="247:257" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.22.e.0" text="eprosartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0287041" phraseText="as 10 mg eprosartan/kg/day." preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="0:19" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.22.e.1" text="eprosartan mesylate" type="Biomedical_Entity"><Normalization><mmtx cui="C0772203" phraseText="Eprosartan mesylate" preferredWord="Eprosartan mesylate" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.22.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.22.e.0"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.25" text="No adverse effects on in utero or postnatal development and maturation of offspring were observed when eprosartan mesylate was administered to pregnant rats at oral doses up to 1000 mg eprosartan/kg/day (the 1000 mg eprosartan/kg/day dose in non-pregnant rats yielded systemic exposure to unbound eprosartan approximately 0.6 times the exposure achieved in humans given 400 mg b.i.d.)." type="negative"><entity charOffset="297:307" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.25.e.0" text="eprosartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0287041" phraseText="systemic exposure to unbound eprosartan approximately 0.6 times" preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="216:226" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.25.e.1" text="eprosartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0287041" phraseText="the 1000 mg eprosartan/kg/day dose in non-pregnant rats" preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="185:195" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.25.e.2" text="eprosartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0287041" phraseText="up to 1000 mg eprosartan/kg/day" preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="103:122" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.25.e.3" text="eprosartan mesylate" type="Biomedical_Entity"><Normalization><mmtx cui="C0772203" phraseText="eprosartan mesylate" preferredWord="Eprosartan mesylate" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.25.e.3" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.25.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.25.e.3" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.25.e.1"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.25.e.3" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.25.e.2"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.27" text="In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with diuretics), symptomatic hypotension may occur. " type="negative"><entity charOffset="36:47" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.27.e.0" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="with an activated renin-angiotensin system," preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="134:143" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.27.e.1" text="diuretics" type="Biomedical_Entity"><Normalization><mmtx cui="C0012798" phraseText="treated with diuretics" preferredWord="Diuretics" semType="phsu"/><RxNorm RxCui="3567"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.27.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.27.e.1"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.33" text="As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function have been reported in susceptible individuals treated with angiotensin II antagonists; " type="negative"><entity charOffset="158:172" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.33.e.0" text="angiotensin ii" type="Biomedical_Entity"><Normalization><mmtx cui="C0003009" phraseText="treated with angiotensin II antagonists" preferredWord="Angiotensin II" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="53:64" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.33.e.1" text="aldosterone" type="Biomedical_Entity"><Normalization><mmtx cui="C0002006" phraseText="the renin-angiotensin-aldosterone system," preferredWord="Aldosterone" semType="strd, phsu, horm"/><RxNorm RxCui="1312358"/></Normalization></entity><entity charOffset="41:52" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.33.e.2" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="the renin-angiotensin-aldosterone system," preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.33.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.33.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.33.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.33.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.33.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.33.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35" lineNumber="31" text="In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. " type="regular"><entity charOffset="174:214" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.0" text="angiotensin-converting enzyme inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="treatment with angiotensin-converting enzyme inhibitors" preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="6162"/></Normalization></entity><entity charOffset="219:254" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.1" text="angiotensin II receptor antagonists" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="angiotensin II receptor antagonists" preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="280:288" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.2" text="oliguria" type="Specific_Interaction"><Normalization><mmtx cui="C0028961" phraseText="associated with oliguria" preferredWord="Oliguria" semType="sosy"/></Normalization></entity><entity charOffset="308:316" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.4" text="azotemia" type="Specific_Interaction"><Normalization><mmtx cui="C0242528" phraseText="progressive azotemia" preferredWord="Azotemia" semType="dsyn"/><mmtx cui="C0554309" phraseText="progressive azotemia" preferredWord="Prerenal uremia syndrome" semType="dsyn"/></Normalization></entity><entity charOffset="335:354" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.6" text="acute renal failure" type="Specific_Interaction"><Normalization><mmtx cui="C0022660" phraseText="with acute renal failure" preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><entity charOffset="362:367" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.8" text="death" type="Specific_Interaction"/><entity charOffset="18:103" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.10" text="renal function may depend on the activity of the renin-angiotensin-aldosterone system" type="SPAN"/><entity charOffset="125:156" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.11" text="severe congestive heart failure" type="SPAN"><Normalization><mmtx cui="C0018802" phraseText="patients with severe congestive heart failure" preferredWord="Congestive heart failure" semType="dsyn"/></Normalization></entity><entity charOffset="280:288" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.12" text="oliguria" type="SPAN"><Normalization><mmtx cui="C0028961" phraseText="associated with oliguria" preferredWord="Oliguria" semType="sosy"/></Normalization></entity><entity charOffset="308:316" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.13" text="azotemia" type="SPAN"><Normalization><mmtx cui="C0242528" phraseText="progressive azotemia" preferredWord="Azotemia" semType="dsyn"/><mmtx cui="C0554309" phraseText="progressive azotemia" preferredWord="Prerenal uremia syndrome" semType="dsyn"/></Normalization></entity><entity charOffset="335:354" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.14" text="acute renal failure" type="SPAN"><Normalization><mmtx cui="C0022660" phraseText="with acute renal failure" preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><entity charOffset="362:367" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.15" text="death" type="SPAN"/><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.ddi.1"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.2"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.1"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.10"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.11"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.ddi.2"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.1"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.10"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.11"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.ddi.3"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.1"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.10"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.11"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.ddi.4"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.8"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.1"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.10"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.11"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.10, Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.11" ddi="true" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.1" trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="1" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36" lineNumber="31" text="TEVETEN  would be expected to behave similarly." type="irregular"><anaphoraRelation><antecedentSentence ID="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35" Text="In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. "/><anaphoraEntity charOffset="30:46" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.1" text="behave similarly" type="Expression"/><antecedentEntity charOffset="280:288" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.2" text="oliguria" type="Specific_Interaction"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35" Text="In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. "/><anaphoraEntity charOffset="30:46" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.1" text="behave similarly" type="Expression"/><antecedentEntity charOffset="280:288" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.12" text="oliguria" type="SPAN"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35" Text="In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. "/><anaphoraEntity charOffset="30:46" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.1" text="behave similarly" type="Expression"/><antecedentEntity charOffset="308:316" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.4" text="azotemia" type="Specific_Interaction"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35" Text="In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. "/><anaphoraEntity charOffset="30:46" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.1" text="behave similarly" type="Expression"/><antecedentEntity charOffset="308:316" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.13" text="azotemia" type="SPAN"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35" Text="In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. "/><anaphoraEntity charOffset="30:46" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.1" text="behave similarly" type="Expression"/><antecedentEntity charOffset="335:354" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.6" text="acute renal failure" type="Specific_Interaction"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35" Text="In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. "/><anaphoraEntity charOffset="30:46" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.1" text="behave similarly" type="Expression"/><antecedentEntity charOffset="335:354" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.14" text="acute renal failure" type="SPAN"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35" Text="In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. "/><anaphoraEntity charOffset="30:46" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.1" text="behave similarly" type="Expression"/><antecedentEntity charOffset="362:367" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.8" text="death" type="Specific_Interaction"/></anaphoraRelation><anaphoraRelation><antecedentSentence ID="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35" Text="In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. "/><anaphoraEntity charOffset="30:46" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.1" text="behave similarly" type="Expression"/><antecedentEntity charOffset="362:367" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.15" text="death" type="SPAN"/></anaphoraRelation><entity charOffset="0:7" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.0" text="TEVETEN" type="Drug"><Normalization><mmtx cui="C0876891" phraseText="TEVETEN" preferredWord="Teveten" semType="phsu, orch"/><RxNorm RxCui="262242"/></Normalization></entity><entity charOffset="30:46" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.2" text="behave similarly" type="Specific_Interaction"/><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.ddi.1"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.2"><relations><relation type="hasPrecipitant"><ellipsisSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35" text="In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. "><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.35.e.0"/></ellipsisSentence></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.36.e.0"/></relation></relations></interaction></drugInteraction></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.46" text="Dual Blockade of the Renin-Angiotensin System (RAS)" type="negative"><entity charOffset="27:38" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.46.e.0" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="Dual Blockade of the Renin-Angiotensin System" preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="5:13" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.46.e.1" text="blockade" type="Biomedical_Entity"><Normalization><mmtx cui="C3540676" phraseText="Dual Blockade of the Renin-Angiotensin System" preferredWord="Blockade" semType="phsu"/><RxNorm RxCui="1423936"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.46.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.46.e.0"/></sentence><sentence biomedicalEntities="3" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47" lineNumber="45" text="Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. " type="irregular"><entity charOffset="30:59" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.0" text="angiotensin receptor blockers" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="with angiotensin receptor blockers," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><mmtx cui="C0815017" phraseText="with angiotensin receptor blockers," preferredWord="Angiotensin Receptor Antagonists" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="61:75" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.1" text="ACE inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="ACE inhibitors," preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="221294"/></Normalization></entity><entity charOffset="80:89" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="128:139" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.3" text="hypotension" type="Specific_Interaction"/><entity charOffset="141:153" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.5" text="hyperkalemia" type="Specific_Interaction"/><entity charOffset="159:184" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.7" text="changes in renal function" type="Specific_Interaction"/><entity charOffset="196:215" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.9" text="acute renal failure" type="Specific_Interaction"><Normalization><mmtx cui="C0022660" phraseText="acute renal failure" preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.ddi.1"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.3"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.42" text="Female patients of childbearing age should be told about the consequences of exposure to TEVETEN during pregnancy. "><entity charOffset="89:96" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.42.e.0" text="TEVETEN" type="Drug"><Normalization><mmtx cui="C0876891" phraseText="to TEVETEN" preferredWord="Teveten" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.43" text="Discuss treatment options with women planning to become pregnant. "/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.44" text="Patients should be asked to report pregnancies to their physicians as soon as possible."/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.45" text="Drug Interactions"/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.46" text="Dual Blockade of the Renin-Angiotensin System (RAS)"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.ddi.2"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.5"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.42" text="Female patients of childbearing age should be told about the consequences of exposure to TEVETEN during pregnancy. "><entity charOffset="89:96" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.42.e.0" text="TEVETEN" type="Drug"><Normalization><mmtx cui="C0876891" phraseText="to TEVETEN" preferredWord="Teveten" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.43" text="Discuss treatment options with women planning to become pregnant. "/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.44" text="Patients should be asked to report pregnancies to their physicians as soon as possible."/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.45" text="Drug Interactions"/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.46" text="Dual Blockade of the Renin-Angiotensin System (RAS)"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.ddi.3"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.7"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.42" text="Female patients of childbearing age should be told about the consequences of exposure to TEVETEN during pregnancy. "><entity charOffset="89:96" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.42.e.0" text="TEVETEN" type="Drug"><Normalization><mmtx cui="C0876891" phraseText="to TEVETEN" preferredWord="Teveten" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.43" text="Discuss treatment options with women planning to become pregnant. "/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.44" text="Patients should be asked to report pregnancies to their physicians as soon as possible."/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.45" text="Drug Interactions"/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.46" text="Dual Blockade of the Renin-Angiotensin System (RAS)"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.ddi.4"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.9"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.42" text="Female patients of childbearing age should be told about the consequences of exposure to TEVETEN during pregnancy. "><entity charOffset="89:96" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.42.e.0" text="TEVETEN" type="Drug"><Normalization><mmtx cui="C0876891" phraseText="to TEVETEN" preferredWord="Teveten" semType="phsu, orch"/></Normalization></entity></ellipsisSentence><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.43" text="Discuss treatment options with women planning to become pregnant. "/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.44" text="Patients should be asked to report pregnancies to their physicians as soon as possible."/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.45" text="Drug Interactions"/><middleSentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.46" text="Dual Blockade of the Renin-Angiotensin System (RAS)"/></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.2"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.1"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.0"/><pair ddi="true" e1="labelDrug" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.47.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.48" lineNumber="45" text="Closely monitor blood pressure, renal function and electrolytes in patients on TEVETEN and other agents that affect the RAS." type="regular"><entity charOffset="8:15" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.48.e.0" text="monitor" type="Caution_Interaction"/><entity charOffset="79:86" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.48.e.2" text="TEVETEN" type="Drug"><Normalization><mmtx cui="C0876891" phraseText="on TEVETEN" preferredWord="Teveten" semType="phsu, orch"/><RxNorm RxCui="262242"/></Normalization></entity><entity charOffset="97:123" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.48.e.3" text="agents that affect the RAS" type="Drug_Class"><Normalization><mmtx cui="C1254351" phraseText="other agents" preferredWord="Pharmacologic Substance" semType="phsu"/><RxNorm RxCui="126263"/></Normalization></entity><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.48.ddi.1"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.48.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.48.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.48.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.48.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.48.e.3" trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.48.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49" lineNumber="47" text="Do not co-administer aliskiren with TEVETEN in patients with diabetes. " type="regular"><entity charOffset="0:20" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.0" text="Do not co-administer" type="Caution_Interaction"/><entity charOffset="21:30" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren with TEVETEN" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="36:43" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.3" text="TEVETEN" type="Drug"><Normalization><mmtx cui="C0876891" phraseText="aliskiren with TEVETEN" preferredWord="Teveten" semType="phsu, orch"/><RxNorm RxCui="262242"/></Normalization></entity><entity charOffset="61:69" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.4" text="diabetes" type="SPAN"><Normalization><mmtx cui="C0011847" phraseText="with diabetes." preferredWord="Diabetes" semType="dsyn"/><mmtx cui="C0011849" phraseText="with diabetes." preferredWord="Diabetes Mellitus" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.ddi.1"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.0"><relations><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.4"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.3"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.4" ddi="true" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.3" trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.49.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50" lineNumber="47" text="Avoid use of aliskiren with TEVETEN in patients with renal impairment (GFR &lt;60 ml/min)." type="regular"><entity charOffset="0:5" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.0" text="Avoid" type="Caution_Interaction"/><entity charOffset="13:22" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="use of aliskiren" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="28:35" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.3" text="TEVETEN" type="Drug"><Normalization><mmtx cui="C0876891" phraseText="with TEVETEN" preferredWord="Teveten" semType="phsu, orch"/><RxNorm RxCui="262242"/></Normalization></entity><entity charOffset="53:69" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.4" text="renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="with renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="with renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.ddi.1"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.3"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.4"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.4" ddi="true" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.3" trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.50.e.0" type="Caution_Interaction"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51" text="Eprosartan has been shown to have no effect on the pharmacokinetics of digoxin and the pharmacodynamics of warfarin and glyburide. " type="negative"><entity charOffset="120:129" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.0" text="glyburide" type="Biomedical_Entity"><Normalization><mmtx cui="C0017628" phraseText="glyburide." preferredWord="Glyburide" semType="phsu, orch"/><RxNorm RxCui="4815"/></Normalization></entity><entity charOffset="0:10" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.1" text="eprosartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0287041" phraseText="Eprosartan" preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="107:115" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.2" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="the pharmacodynamics of warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="71:78" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.3" text="digoxin" type="Biomedical_Entity"><Normalization><mmtx cui="C0012265" phraseText="no effect on the pharmacokinetics of digoxin" preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.3" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.2"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.3"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.3" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.51.e.2"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53" text="Because eprosartan is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and ketoconazole and fluconazole, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on eprosartan pharmacokinetics. " type="negative"><entity charOffset="69:96" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.0" text="inhibitors enzyme" type="Biomedical_Entity"><Normalization><mmtx cui="C0014432" phraseText="inhibitors of CYP450 enzyme" preferredWord="Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="149:161" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.1" text="ketoconazole" type="Biomedical_Entity"><Normalization><mmtx cui="C0022625" phraseText="ketoconazole" preferredWord="Ketoconazole" semType="phsu, orch"/><RxNorm RxCui="6135"/></Normalization></entity><entity charOffset="266:276" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.2" text="eprosartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0287041" phraseText="no effect on eprosartan pharmacokinetics." preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="166:177" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.3" text="fluconazole" type="Biomedical_Entity"><Normalization><mmtx cui="C0016277" phraseText="fluconazole," preferredWord="Fluconazole" semType="phsu, orch"/><RxNorm RxCui="4450"/></Normalization></entity><entity charOffset="8:18" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.4" text="eprosartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0287041" phraseText="eprosartan" preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.1"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.2"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.3"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.4" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.2"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.3"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.4" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.1"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.3" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.2"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.4" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.53.e.3"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.54" text="Ranitidine also has no effect on eprosartan pharmacokinetics." type="negative"><entity charOffset="0:10" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.54.e.0" text="ranitidine" type="Biomedical_Entity"><Normalization><mmtx cui="C0034665" phraseText="Ranitidine also" preferredWord="Ranitidine" semType="phsu, orch"/><RxNorm RxCui="203136"/></Normalization></entity><entity charOffset="33:43" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.54.e.1" text="eprosartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0287041" phraseText="no effect on eprosartan pharmacokinetics." preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.54.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.54.e.1"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.55" text="Eprosartan (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a thiazide diuretic (hydrochlorothiazide). " type="negative"><entity charOffset="97:114" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.55.e.0" text="thiazide diuretic" type="Biomedical_Entity"><Normalization><mmtx cui="C3536861" phraseText="concomitantly with a thiazide diuretic" preferredWord="Thiazide Diuretic [EPC]" semType="phsu"/><RxNorm RxCui="141801"/></Normalization></entity><entity charOffset="0:10" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.55.e.1" text="eprosartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0287041" phraseText="Eprosartan" preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="116:135" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.55.e.2" text="hydrochlorothiazide" type="Biomedical_Entity"><Normalization><mmtx cui="C0020261" phraseText="(hydrochlorothiazide" preferredWord="Hydrochlorothiazide" semType="phsu, orch"/><RxNorm RxCui="5487"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.55.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.55.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.55.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.55.e.2"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.55.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.55.e.2"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.56" text="Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release nifedipine) with no clinically significant adverse interactions." type="negative"><entity charOffset="99:123" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.56.e.0" text="calcium channel blockers" type="Biomedical_Entity"><Normalization><mmtx cui="C0006684" phraseText="concomitantly with sustained-release calcium channel blockers" preferredWord="Calcium Channel Blockers" semType="phsu"/><RxNorm RxCui="1895"/></Normalization></entity><entity charOffset="0:10" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.56.e.1" text="eprosartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0287041" phraseText="Eprosartan doses of" preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="143:153" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.56.e.2" text="nifedipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0028066" phraseText="(sustained-release nifedipine" preferredWord="Nifedipine" semType="phsu, orch"/><RxNorm RxCui="7417"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.56.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.56.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.56.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.56.e.2"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.56.e.1" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.56.e.2"/></sentence><sentence id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.57" text="Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)" type="negative"><entity charOffset="59:86" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.57.e.0" text="cyclooxygenase-2 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1257954" phraseText="Selective Cyclooxygenase-2 Inhibitors" preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="119049"/></Normalization></entity><entity charOffset="88:104" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.57.e.1" text="cox-2 inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C1257954" phraseText="(COX-2 Inhibitors" preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="382306"/></Normalization></entity><entity charOffset="0:38" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.57.e.2" text="non-steroidal anti-inflammatory agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003211" phraseText="Non-Steroidal Anti-Inflammatory Agents" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="1005832"/></Normalization></entity><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.57.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.57.e.0"/><pair ddi="false" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.57.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.57.e.1"/></sentence><sentence biomedicalEntities="4" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58" lineNumber="55" text="In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including eprosartan, may result in deterioration of renal function, including possible acute renal failure. " type="regular"><entity charOffset="20:27" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.0" text="elderly" type="SPAN"/><entity charOffset="29:44" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.1" text="volume-depleted" type="SPAN"/><entity charOffset="92:118" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.2" text="compromised renal function" type="SPAN"/><entity charOffset="141:147" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.3" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="co-administration of NSAIDs," preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="159:185" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.4" text="selective COX-2 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1257954" phraseText="selective COX-2 inhibitors," preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="1431714"/></Normalization></entity><entity charOffset="192:227" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.6" text="angiotensin II receptor antagonists" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="with angiotensin II receptor antagonists," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="239:249" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.7" text="eprosartan" type="Drug"><Normalization><mmtx cui="C0287041" phraseText="eprosartan," preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="265:296" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.9" text="deterioration of renal function" type="Specific_Interaction"/><entity charOffset="317:336" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.11" text="acute renal failure" type="Specific_Interaction"><Normalization><mmtx cui="C0022660" phraseText="possible acute renal failure." preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><classClassMembership drugClass="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.4"/><drugClassMembership drug="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.7" drugClass="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.6"/><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.ddi.1"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.9"><relations><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.1"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.6"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.3"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.ddi.2"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.11"><relations><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.1"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.6"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.3"/></relation><relation type="hasContext"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.2"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.1, Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.0, Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.2" ddi="true" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.3" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.6" trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.58.e.9" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.60" lineNumber="55" text="Monitor renal function periodically in patients receiving eprosartan and NSAID therapy." type="regular"><entity charOffset="0:7" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.60.e.0" text="Monitor" type="Caution_Interaction"/><entity charOffset="58:68" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.60.e.2" text="eprosartan" type="Drug"><Normalization><mmtx cui="C0287041" phraseText="eprosartan" preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="73:78" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.60.e.3" text="NSAID" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="NSAID therapy." preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.60.ddi.1"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.60.e.0"><relations><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.60.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.60.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.60.e.2" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.60.e.3" trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.60.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="4" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61" lineNumber="57" text="The antihypertensive effect of angiotensin II receptor antagonists, including eprosartan may be attenuated by NSAIDs including selective COX-2 inhibitors." type="regular"><entity charOffset="31:66" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.0" text="angiotensin II receptor antagonists" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="The antihypertensive effect of angiotensin II receptor antagonists," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="78:88" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.1" text="eprosartan" type="Drug"><Normalization><mmtx cui="C0287041" phraseText="eprosartan" preferredWord="eprosartan" semType="phsu, orch"/><RxNorm RxCui="236878"/></Normalization></entity><entity charOffset="127:153" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.3" text="selective COX-2 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1257954" phraseText="selective COX-2 inhibitors." preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="1431714"/></Normalization></entity><entity charOffset="110:116" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.4" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="attenuated by NSAIDs" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="4:27|89:106" id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.6" text="antihypertensive effect may be attenuated" type="Specific_Interaction"/><drugClassMembership drug="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.1" drugClass="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.0"/><classClassMembership drugClass="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.3"/><drugInteraction id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.ddi.1"><interaction trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.0" e2="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.4" trigger="Dailymed.7cde57a7-eded-4c22-b1c7-98afc5546997.s.61.e.6" type="Specific_Interaction"/></sentence><positiveExamples number="11"/><negativeExamples number="42"/></document>